Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

Clinical and Translational Oncology

Volumn 17, Issue 2, 2015, Pages 160-166

  Salvador, J ^a   Manso, L ^b   de la Haba, J ^c   Jaen, A ^d   Ciruelos, E ^b   de Villena, M C ^e   Gil, M ^f   Murias, A ^g   Galan, A ^h   Jara, C ⁱ   Bayo, J ^j   Baena, J M ^k   Casal, J ^l   Mel, J R ^m   Blancas, I ⁿ   Sanchez Rvira, P ^d  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d Hosp Univ Ciudad de Jaén   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^f L Hospitalet de Llobregat   (Spain)

^g HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^h HOSPITAL DE SAGUNTO   (Spain)

ⁱ HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^j HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^k HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^l HOSPITAL DO MEIXOEIRO   (Spain)

^m HOSPITAL XERAL CALDE   (Spain)

ⁿ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

more..

Author keywords

Bevacizumab; Gemcitabine; Metastatic breast cancer; Paclitaxel

Indexed keywords

AGTR1 PROTEIN, HUMAN; ANGIOTENSIN 1 RECEPTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; MONOCLONAL ANTIBODY; PACLITAXEL;

ADULT; AGED; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; SURVIVAL RATE; TRANSLATIONAL RESEARCH; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PACLITAXEL; PROGNOSIS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ERBB-2; SURVIVAL RATE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84939880649     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-014-1210-x     Document Type: Article

References (20)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2012; 62(4):220–41. doi:10.3322/caac.21149
2. Bosetti C, Bertuccio P, Levi F, Lucchini F, Negri E, La Vecchia C. Cancer mortality in the European Union, 1970–2003, with a joinpoint analysis. Ann Oncol. 2008; 19(4):631–40. Epub 2008 Feb 14.
3. Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v15–9.
4. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976–83.
5. Delfino C, Caccia GM, Riva Gonzales L, Mickiewicz E.: Gemcitabine plus paclitaxel administered as firstline chemotherapy for patients with advanced breast cancer (ABC). Proc Am Soc Clin Oncol. 2002;21:53b (abstr 2025).
6. Murad AM, Guimaraes RC, Aragao BC, Scalabrini-Neto AO, Rodrigues VH, Garcia R. Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer. Am J Clin Oncol. 2001;24:264–8.
7. Demiray M, Kurt E, Evrensel T, Kanat O, Arslan M, Saraydaroglu O, et al. Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure. Cancer Invest. 2005;23:386–91.
8. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26(24):3950–7.
9. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible of angiogenesis. J Exp Med. 1971;133(2):276–88
10. O’Shaughnessy J, Miles D, Gray R, Dieras V, Perez E, Zon R, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2010;28(suppl):abstr 1005.
11. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.
12. Zielinski C, Lang I, Inbar M, Kahan Z, Greil R, Beslija S, et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab containing regimens as first line therapy for HER-2 negative metastatic breast cancer. Annals of Oncology 2012;23(supplement 9) abstract 3170.
13. Bidard FC, Mathiot C, Degeorges A, Etienne-Grimaldi MC, Delva R, Pivot X, et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol. 2010;21(9):1765–71. Epub 2010 Mar 16.
14. Sanchez-Rovira P, de la Haba-Rodriguez J, Fernandez-Navarro M, Segui M, Llombart-Cussac A, Anton A, et al. Predictive response factors in an open non- randomized phase II study of a combination of bevacizumab and sequential chemotherapy as preoperative treatment in patients with operable Her-2 negative breast cancer. J Clin Oncol 2010;28:(suppl; abstr 556).
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
16. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101:1642–9.
17. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol. 2010;28:1958–62.
18. Brufsky A, Hoelzer K, Beck T, Whorf R, Keaton M, Nadella P, et al. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer. Clin Breast Cancer. 2011;11(4):211–220. Epub 2011 Jul 1.
19. Rugo H, Dickler M.N, Traina TA, Scott JH, Park JW. Change in circulating endothelial cells (CEC) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevacizumab (B). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 3039.
20. Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci USA. 2009;106(25):10284–9. Epub 2009 Jun 1.